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Background: A new subset of T helper (Th) cells, named IL-22-producing Th22 cells, was identified recently. Th22
cells have been implicated in immunity and inflammation. However, the role of these cells in the progression from
acute viral myocarditis (AVMC) to dilated cardiomyopathy (DCM) and myocardial fibrosis remains unknown.
Methods: BALB/c mice were repeatedly i.p. infected with Coxsackie virus B3 (CVB3) to establish models of AVMC,
chronic myocarditis and DCM. On week 2, 12 and 24 post initial injection, the percentage of splenic Th22 cells, the
levels of plasma IL-22, cardiac IL-22 receptor (IL-22R) expression, and indicators of myocardial fibrosis were measured.
Further, mice with AVMC and chronic myocarditis were treated with an anti-IL-22 neutralizing antibody (Ab). The
collagen volume fraction (CVF), the percentage of splenic Th22 cells, plasma IL-22 levels, cardiac IL-22R expression and
indicators of myocardial fibrosis were then monitored.
Results: Compared to control mice at the same time points, AVMC, chronic myocarditis and DCM mice have higher
percentage of splenic Th22 cells, higher plasma IL-22 levels, increased cardiac IL-22R, as well as increased collagen
typeI-A1 (COL1-A1), collagen type III-A1 (COL3-A1) and matrix metalloproteinase-9 (MMP9) expression. However, the
expression of tissue inhibitor of metalloproteinase-1(TIMP-1) was decreased. Treatment of AVMC and chronic myocarditis
mice with an anti-IL-22 Ab decreased the survival rate and exacerbated myocardial fibrosis. The percentage of splenic
Th22 cells, plasma IL-22 levels and cardiac IL-22R expression also decreased in anti-IL-22 Ab treatment group as
compared to IgG and PBS treated groups of AVMC and chronic myocarditis mice. Moreover, increased expression of
COL1-A1, COL3-A1, MMP9 but decreased expression of TIMP-1 were observed in anti-IL-22 Ab mouse group.
Conclusions: Th22 cells play an important role in the pathogenesis of CVB3-induced mouse chronic myocarditis and
DCM. IL-22 is a myocardium-protective cytokine by inhibiting myocardial fibrosis. Therefore, Th 22 cells may be
considered as potential therapeutic targets for DCM.
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Viral myocarditis (VMC) is a common cardiac disease,
characterized by myocardial inflammation due to virus
infection. It was confirmed that the persistence of viral
infection exists in some individuals with chronic myo-
carditis and dilated cardiomyopathy (DCM). Some pa-
tients with VMC may progress to chronic myocarditis
and DCM, a terminal condition of heart failure and
heart transplantation [1].* Correspondence: wucna65@163.com
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fibrosis is a major determinant in the development from
VMC to DCM [2-4]. But the mechanism of myocardial fi-
brosis in disease procession has not been elucidated. It has
been reported that T helper (Th) 1- and Th17-cell medi-
ated autoimmune destruction may play an important role
in myocardial fibrosis in which VMC progresses to DCM.
However, Th1 and Th17 cell subsets may not fully explain
the disease mechanism, because results from clinical trial
and animal experiments concerning these T cell subsets
were inconsistent [5-8].is is an Open Access article distributed under the terms of the Creative
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primarily secrete IL-22. These cells do not express IL-
17, IL-4, or IFN-γ [9,10]. IL-22 exerts its effect through
IL-22R, which is a heterodimeric transmembrane recep-
tor complex consisting of IL-22R1 and IL-10R2 [11].
Th22 cells play a key role in autoimmune tissue injury,
including organ-specific autoimmunity [9]. Our previous
studies have found that CVB3-induced AVMC mice
have higher number of IL-22-producing Th22 cells and
IL-22 shows critical anti-inflammatory and antiviral ac-
tivity in disease development [12].
However, the role of Th22 cells and the mechanism of
myocardial fibrosis in the course from AVMC to DCM
are not clear. Therefore, our present study attempted to
detect the percentage of Th22 cells, plasma IL-22 levels
and cardiac IL-22R expression at stage of chronic myo-
carditis and DCM. We further explored the effect of
neutralizing anti-IL-22 antibody (Ab) on myocardial fi-
brosis. Our study provided new insights into the role of
Th22 cells in chronic myocarditis and DCM.
Results
Evaluation of the severity of AVMC, chronic myocarditis
and DCM
The characteristic signs in mice with AVMC, chronic
myocarditis and DCM, including weakness, weight loss,
irritability, back arching, coat ruffling, and lethargy were
observed. After initial viral injection, 4 of 20 mice died
in the AVMC group, 6 of 20 and 11 of 30 mice died in
the chronic myocarditis and DCM groups. In contrast,
no mice died in control groups. In sections of heart tis-
sues from AVMC mice, larger numbers of inflammatory
cells and necrosis with destruction of myocardial fibers
were observed. At this stage, myocardial fibrosis was not
visible. Inflammatory cells then decreased and myocardial
collagen fibers increased with compensatory hypertrophy
of myocardial cells. Necrotic myocardial cells gradually re-
placed by fibrous tissue at the stage of chronic myocardi-
tis. In DCM mice, myocardial fibers were disorganized,
with no inflammatory cell infiltration. Cardiomyocytes
were seperated into several patchy areas by a numerous
myocardial collagen fibers (Figure 1). The results indicate
that the severity of myocardial fibrosis gradually increased
with progression from AVMC to DCM.
Exacerbation of myocardial fibrosis from AVMC to DCM
The expression of collagen typeI-A1 (COL1-A1) gene in
myocardium significantly elevated in all virus infected
mice by comparison to control mice at the same time
points (Figure 2A). In addition, the expression of COL1-
A1 gene increased with the progression from AVMC to
DCM. As shown in Figure 2A, compared to control mice,
the levels of circulating COL1-A1 were significantly higher
in mice with chronic myocarditis and DCM. Similarly, theexpression of collagen type III-A1 (COL3-A1) gene in
myocardium significantly elevated in mice treated with
CVB3 (Figure 2B). Compared with control mice, higher
levels of cardiac matrix metalloproteinase-9 (MMP9) gene
and circulating MMP9 were detected in AVMC, chronic
myocarditis and DCM mice (Figure 2C). We also observed
alterations of cardiac tissue inhibitor of metalloproteinase-
1(TIMP-1) gene and plasma TIMP-1. Data in Figure 2D
confirmed that the levels of circulating TIMP-1 markedly
decreased in mice with chronic myocarditis and DCM.
The expression of TIMP-1 mRNA was not statistically dif-
ferent. Figure 2E shows that much higher ratio of MMP9/
TIMP-1 was detected in AVMC, chronic myocarditis and
DCM mice. Higher collagen volume fraction (CVF) was
observed in mice receiving virus, revealing progressive in-
crease in the course from AVMC to DCM (Figure 2F).
With the progression from AVMC to DCM, the severity
of myocardial fibrosis significantly increased accompanied
by up-regulation of COL1-A1, COLA3-A1, MMP9 and ra-
tio of MMP9/TIMP-1 but down-regulation of TIMP-1.
Increased proportions of splenic Th22, plasma IL-22 levels
and myocardial IL-22R expression in AVMC, chronic myo-
carditis and DCM mice
Flow cytometry was used to analyze mononuclear cells
from freshly isolated spleen of mice week 2, 12 and 24
post initial viral injection (Figure 3A). Figure 3B shows
that the percentage of Th22 cells (IL-22 + IL-17-IFN-γ-
CD4+) increased in mice with AVMC (4.64 ± 2.35%),
chronic myocarditis (5.90 ± 1.74%) and DCM (5.60 ±
1.47%) relative to control mice (1.78 ± 0.79%, 1.50 ±
0.44%, 1.75 ± 0.30%, respectively). However, compared to
chronic myocarditis mice, the percentage of splenic
Th22 cells in DCM mice exhibited only a slight de-
crease. Th22 cell numbers among three mouse groups
treated with virus were of no statistically significant dif-
ference. The levels of plasma IL-22 in mice with AVMC,
chronic myocarditis and DCM markedly increased as
compared to control mice (Figure 3C). Also, the expres-
sion of IL-22R protein was up-regulated in AVMC,
chronic myocarditis and DCM mouse groups, compared
to control mice (Figure 4A and B). Spearman rank cor-
relation coefficients shown in Figures 3D and 4C dem-
onstrated that the percentage of Th22 cells positively
correlated with circulating IL-22 levels and cardiac IL-
22R protein. Figures 3 and 4 show higher proportions of
splenic Th22 cells, plasma IL-22 levels and myocardial
IL-22R expression in AVMC, chronic myocarditis and
DCM mice.
Neutralization of IL-22 exacerbated the severity of AVMC
and chronic myocarditis and the procession to DCM
Four out of 10 mice and 3 out of 10 mice survived at 2
and 12 weeks after viral infection in anti-IL-22 treatment
Figure 1 The severity of AVMC, chronic myocarditis and DCM. A. Representative myocardial histopathologic images in AVMC, chronic
myocarditis and DCM (H&E, original magnification × 400). B. Representative myocardial fibrosis images in AVMC, chronic myocarditis and DCM
(Masson’s Trichrome, original magnification × 400).
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survived at 2 and 12 weeks after initial infection in IgG
treatment subgroup and 8 out of 10 mice and 7 out 10
mice in the PBS treated subgroup. Compared to IgG
and PBS treatment subgroups, the survive rate of mice
treated with anti-IL-22 Ab at week 2 and 12 was signifi-
cant lower (Figure 5A). However, there was no differ-
ence in survival rate in IgG and PBS treatment
subgroups. The CVF of myocardium in anti-IL-22 Ab
treated mice exhibited a moderate increase compared to
other mouse groups at week 2, but without statistical
significance. Higher CVF was detected in mice receiving
anti-IL-22 Ab at week 12 (Figure 5B). The increasedlevel of CVF was similar to DCM mouse group (0.30 ±
0.07 vs. 0.24 ± 0.09, p > 0.05). The difference of CVF in IgG
and PBS mouse subgroups was not significant. Figure 5C
showed the severity of myocardial fibrosis in week 2 and 12
mouse groups. Anti-IL-22Ab treatment exacerbated the se-
verity of AVMC and chronic myocarditis and accelerated
the procession to DCM.
Neutralization of IL-22 decreased the percentage of
splenic Th22 cells, plasma IL-22 levels and cardiac
IL-22R expression
The percentage of splenic Th22 cells was examined at
week 2 and 12 (Figure 6A). Th22 cells in mice treated
Figure 2 Aggravated myocardial fibrosis from AVMC to DCM. A. Cardiac expression of COL1-A1 was investigated by RT-PCR, and the level of
circulating protein was measured by ELISA. B. Cardiac COL3-A1 expression in mice treated with virus. C-D. Cardiac MMP9 and TIMP-1 expression
and circulating protein. E. The ratio of MMP9/TIMP-1 mRNA. F. CVF of mice receiving virus showing a progressive increase in the course from
AVMC to DCM. *p < 0.05, **p < 0.01. Data are means ± SD.
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subgroups (p < 0.05). As shown in Figure 6B, C and D, a
marked reduction in circulating IL-22 and IL-22R ex-
pression in myocardium were observed in anti-IL-22 Ab
treated mice. Th22 cells, IL-22 and IL-22R in IgG and
PBS treated mouse subgroups remained at higher levels.
There was no significant difference between IgG and
PBS treated mice. Figure 6 showed that the percentage
of splenic Th22 cells, circulating IL-22 and cardiac IL-
22R expression decreased after neutralization of IL-22.
Neutralization of IL-22 exacerbated myocardial fibrosis
After neutralization of IL-22, the indicators of myocar-
dial fibrosis were investigated at week 2 and 12. The
levels of circulating COL1-A1 significantly elevated in
anti-IL-22 Ab treated subgroup by comparison to IgG
and PBS treated subgroups at week 12 (Figure 7A). Asshown in Figure 7A, in anti-IL-22 Ab treated subgroup,
the levels of circulating COL1-A1 was higher at week 2
and the expression of COL1-A1 gene in myocardium at
week 2 and 12 was up-regulated, but without statistical
significance compared to other mouse subgroups. Myo-
cardium COL3-A1 mRNA was elevated in anti-IL-22 Ab
treated mice at week 2 and 12 (Figure 7B). At week 12,
the up-regulation of COL3-A1 gene in anti-IL-22 Ab-
treated mice was similar to DCM mice. Figure 7C
showed that, at week 2 and 12, much higher ratio of
MMP9/TIMP-1 was observed in anti-IL-22 Ab treated
mouse subgroup. Much higher levels of MMP9 tran-
scripts in myocardium and circulating MMP9 were de-
tected in anti-IL-22 Ab treated mouse subgroup at week
2 and 12 (Figure 7D, both p < 0.01). Data in Figure 7E
confirmed decreased circulating TIMP-1 in mice receiv-
ing anti-IL-22 Ab at week 2 and 12, compared to IgG
Figure 3 Increased percentage of Th22 cells and circulating IL-22 in AVMC, chronic myocarditis and DCM. A. Th22 cells identified based
on expressions of IL-22 + IL-17-IFN-γ-CD4 +. B. Comparisons of Th22 cells in mice of AVMC, chronic myocarditis and DCM groups with control
mice at the same time points. C. Up-regulation of circulating IL-22 detected in AVMC, chronic myocarditis and DCM mice. D. Correlation of the percentage
of splenic Th22 cells with circulating IL-22.
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mRNA showed a little decrease in anti-IL-22 Ab treated
mice at week 2 (p > 0.05). However, at week 12, marked
increase was observed (p < 0.01). Data in this figure
showed that statistically significant difference in the
levels of COL1-A1, COL3-A1, MMP9, TIMP-1 andFigure 4 Up-regulated cardiac IL-22R expression in AVMC, chronic my
images in heart tissue (Dark brown granules, original magnification × 400).
the percentage of splenic Th22 cells with cardiac IL-22R. *p < 0.05, **p < 0.0MMP9/TIMP-1 between IgG control and PBS sub-
groups was not been investigated on week 2 and week
12. Neutralization of IL-22 exacerbated myocardial fi-
brosis with down-regulation of the percentage of splenic
Th22 cells, circulating IL-22 and myocardial IL-22R
expression.ocarditis and DCM. A. Representative IL-22R immunohistochemistry
B. Morphometric quantitation of cardiac IL-22 protein. C. Correlation of
1. Data are the means ± SD.
Figure 5 Neutralization of IL-22 exacerbated the severity of AVMC and chronic myocarditis. A. Survival rate of anti-IL-22 Ab treated mice
at week 2 and 12 after neutralization of IL-22. B. CVF of mice in anti-IL-22 Ab subgroup at week 12. C. Representative myocardial fibrosis images
in anti-IL-22 Ab, IgG and PBS treated mice at week 2 and 12 (Masson’s Trichrome, original magnification × 100).
Guo et al. Virology Journal  (2014) 11:230 Page 7 of 12Discussion
VMC is a common cardiac disease and some patients
with VMC may progress to chronic myocarditis and
DCM, with a terminal condition of heart failure requir-
ing heart transplantation. The main characteristic of
DCM is extensive myocardial fibrosis, due to cardiomyo-
cyte death and accumulation of extracellular matrix
(ECM) protein. The main collagens in ECM are type I
(50–85%) and type III (10–45%) collagens [13]. We ob-
served that the degree of myocardial fibrosis gradually in-
creased with the progression from AVMC to DCM,
accompanied by up-regulation of COL1-A1 and COLA3-
A1. The role of MMP9 in infectious and autoimmune dis-
eases was not clear, research with inconsistent reports
[14-17]. TIMPs are inhibitors of MMPs, which disturb the
pathological consequences through MMPs [18]. The
MMP/TIMP-1 ratio is correlated to the heart injury. Our
data showed increased MMP9 level, MMP9/TIMP-1 ratioand decreased TIMP-1 level in AVMC, chronic myocardi-
tis and DCM mice. Up-regulation of MMP9, MMP9/
TIMP-1 ratio and down-regulation of TIMP-1 were more
significant after neutralizing IL-22, associated with myo-
cardial fibrosis exacerbation. Therefore, MMP-9 may act
as a damaging factor in the pathogenesis of DCM.
Growing evidence suggests that Th22 cells may play
an important role in autoimmune disease such as sys-
temic lupus erythematosus [19], oral and cutaneous
Lichen Planus lesions [20], neuromyelitis optica, mul-
tiple sclerosis [21], psoriasis, psoriatic arthritis [22,23]
and IgA nephropathy [24], as well as infectious disease
including chronic HIV infection [25] and hepatitis
[26,27]. Recently, Th22 cells have been implicated in
endocrine and cardiovascular diseases, such as type 1
diabetes [28], type 2 diabetes and obesity [29], acute
coronary syndrome [30], coxsackievirus B3 (CVB3)-in-
duced acute viral myocarditis [12] and DCM [31].
Figure 6 Neutralization of IL-22 decreased the percentage of the Th22 cells, IL-22 and IL-22R. A. Th22 cells in anti-IL-22 Ab, IgG and PBS
treated mouse groups were investigated by flow cytometry at week 2 and 12. B. The levels of circulating IL-22 measured by ELISA. C. Morphometric
quantitation of cardiac IL-22R protein expression detected by IHC. D. Representative IL-22R immunohistochemistry images in heart tissue in anti-IL-22
Ab, IgG control and PBS treated mouse groups (Dark brown granules, original magnification × 400).
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may be a double-edged sword. Th22 cells and IL-22 have
critical anti-inflammatory and antiviral effect in CVB3-
induced mouse AVMC [12]. However, in IL-17A-deficient
mice, IL-22 exacerbates CVB3-induced acute viral myo-
carditis [32]. Similar results were reported [33] concerning
either protective and proinflammatory effects of Th22
cells. Our data showed that, compared with control mice
at the same time points, the percentage of the pure Th22
cell, plasma IL-22 and cardiac protein expression of IL-
22R were up-regulated in AVMC, chronic myocarditis and
DCM groups. Then the myocardial fibrosis increased and
survival rate decreased in mice after neutralizing IL-22, ac-
companied by a decline in Th22 cell number, reduced IL-
22, diminished IL-22R expression and increased indicators
of myocardial fibrosis such as COL1-A1, COL3-A1,
MMP9. Moreover, the severity of myocardial fibrosis in
chronic myocarditis after neutralizing IL-22 is similar to
DCM. These results revealed that neutralization of IL-22
exacerbated the severity of AVMC and chronic myocardi-
tis, aggravated myocardial fibrosis and accelerated theprocession of DCM. Thus, Th22 cells and IL-22 play a
protective role in DCM by inhibiting myocardial fibrosis
and act as therapeutic targets.
However, there are several limitations in our study.
First of all, the small number of mice, especially survival
mice after neutralization of IL-22, may have a causal ef-
fect on outcome. In addition, the circulating IL-22
in vivo may not be completely antagonized using the
injected dose of anti-IL-22 Ab. Other cells such as NKT,
Th17 etc. can produce IL-22, those cells may interfere
with the study of th22 cell function. As part of future ef-
forts, it will be important to increase the number of
mice and eliminate circulating IL-22 as much as pos-
sible, knockout mice may be used if necessary to con-
firm our results further.
Conclusions
In summary, our study demonstrated that the up-
regulations of IL-22-producing Th22 cells may play an im-
portant part in the pathogenesis of CVB3-induced mice
chronic myocarditis and DCM by inhibiting myocardial
Figure 7 (See legend on next page.)
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Figure 7 Neutralization of IL-22 exacerbated myocardial fibrosis at stages of AVMC and chronic myocarditis. A. Relative cardiac
expression and plasma levels of COL1-A1 detected at week 2 and 12, measured by RT-PCR and ELISA. B. Up-regulation of cardiac expression of
COL3-A1 in anti-IL-22 Ab treated mice. C. The ratio of MMP9/TIMP-1 mRNA. D-E. Higher MMP9 and lower TIMP-1 detected in anti-IL-22 Ab treated
mice. *p < 0.05, **p < 0.01. Data are the means ± SD.
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kine by means of decreasing COL1-A1, COL3-A1, MMP9
and increasing TIMP-1. In order to explore the thera-
peutic potential of Th22 cells in the progression from
AVMC to DCM, future studies, which focus on regulating
the downstream pathways of Th22 cells would be more
promising.Methods
Mice
Pathogen-free male BALB/c mice aged 4 week were pur-
chased from the Guangdong Medical Laboratory Animal
Centre, Foshan, China (Certificate No. SCXK (Yue) 2008–
0002). All animals were kept in pathogen-free mouse
room in Experimental Animal Center of the Guangxi
Medical University, Nanning, China. All experiments were
carried out in accordance with protocols approved by
Guangxi Medical University Animal Ethics Committee.Virus
CVB3 (Nancy strain, from Institute of immunology of
Guangxi Medical University) was maintained by passa-
ging through Hep-2 cells. Virus titer was determined by
plaque-forming unit (PFU) assay at 1 × 108. CVB3 was
diluted in phosphate-buffered saline (PBS) (Solarbio Sci-
ence &Technology Co, Ltd, Beijing, China).Induction of AVMC, chronic myocarditis and DCM
BALB/c mice were infected by intraperitoneal injection
(i.p) of 100 μl PBS containing approximately ~ 106 PFUs
of the virus for establishing AVMC. For chronic myocardi-
tis and DMC, BALB/c mice were infected by the same
dose of virus on day 0. Subsequently the virus was injected
once every 4 weeks in increments of 10 μl in a total of
three doses for establishing chronic myocarditis and six
doses for establishing DCM.
One hundred BALB/c mice were randomly divided
into four groups: 1) 20 in the AVMC group; 2) 20 in
chronic myocarditis group; 3) 20 in DCM group; and 4)
the rest mice as a PBS injection control group (n = 30).
All surviving animals with AVMC and 10 control mice
were sacrificed by the end of week 2 after infection. In
chronic myocarditis and DCM, surviving animals and 10
control mice were sacrificed by the end of week 12 and
24, respectively. Heart and spleen were removed aseptic-
ally and blood was harvested to obtain plasma.Neutralization of IL-22
A total of 60 mice infected with CVB3 were randomly
divided into two groups: 1) week 2 group, in which all
surviving animals were sacrificed on day 14 after CVB3
infection, and 2) week 12 group, on day 84 after treat-
ment with CVB3, all surviving mice were sacrificed. Each
mouse group was separated into three subgroups: i.p. ad-
ministration of anti-IL-22 Ab (50 μg per mouse every
4 weeks, at day 0, day 28 and day 56, n = 10, anti-IL-22Ab
subgroup); normal IgG control (50 μg per mouse; n = 10,
IgG control subgroup) and PBS (50 μg per mouse; n = 10,
PBS subgroup). Anti-IL-22 Ab and normal IgG were from
R&D Systems, Inc. Minneapolis. The survival rates of each
mouse group were recorded and plasma, hearts and
spleens of surviving mice were harvested on day 14 in
week 2 group and day 84 in week 12 group.
Histopathology
The left-ventricular tissues of the mouse heart were fixed
in 10% formalin, then were embedded in paraffin. The tis-
sues were incised into 5-μm sections along the length of
the heart, and stained with H&E (hematoxylin and eosin)
or Masson’s Trichrome. Histopathological changes were
observed (Olympus BX53 Microscope, Tokyo, Japan).
Flow cytometry
Spleens from mice were collected to prepare a single-
cell suspension. The cells were resuspended in RPMI
1640 (Wisent, Nanjing, China) medium with 10% Super-
ior Placental Bovine Serum (sijiqing, Hangzhou, China)
and stimulated with phorbol myristate acetate (PMA,
25 ng/ml, Sigma-Aldrich, USA) and ionomycin (1 μg/ml,
Sigma-Aldrich, USA) in the presence of GolgiPlug (1ul/106
cells, BD Biosciences, USA) at 37°C, 5% CO2 in 24-well
culture plate. After 5 h incubation, the cells were harvested
and stained with PERCP-CY5.5 conjugated anti-mouse
CD4 (PERCP-CY5.5-CD4, BD Biosciences). The cells were
stained intracellularly with anti–IL-22, −IL-17, or –IFN-γ
mAb conjugated with PE, APC, or FITC after fixation and
permeabilization (BD Biosciences, eBioscience), then ana-
lyzed on a FACS-Calibur flow cytometer (BD Bioscience).
FlowJo 7.6 (Treestar, USA) was used for data acquisition.
Th22 cells were defined as IL-22 + IL-17-IFN-γ-CD4 +.
Immunohistochemistry
Rabbit polyclonal antibodies against mouse IL-22R
(Bioss, Beijing, China) were used as primary antibodies
at a 1: 200 dilution. The heart sections were stained by
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China). After the sections were rehydrated, endogen-
ous peroxidase activity was blocked with 3% hydrogen
peroxide for 10 min at room temperature. The sections
were then incubated in 5% bovine serum albumin for
20 min followed by in the primary antibody at 4°C for
24 h. The sections were incubated with streptavidin-
biotin complex for 20 min and visualized with 3, 3-
diaminobenzidine (Boster, Wuhan, China) under a
light microscope. Non-immune goat serum was used
as a control. IL-22R in the cytoplasm and cytomem-
brane of myocardium was evaluated semi-quantitatively
using Image-Pro Plus Version 6.0 (Media Cybernetics,
Bethesda, MD). 5 fields from each slice were randomly
selected by two pathologists to measure integrated op-
tical density (IOD).
Real-time RT-PCR
Total RNA of homogenized left-ventricular tissues of
the mouse heart was extracted with TRIZOL Reagent®
(Invitrogen, USA), and then reverse transcripted into
cDNA with a Reverse Transcription kit (Takara, Dalian,
China). Primers for COL1-A1, COL3-A1, MMP-9, TIMP-1
and the housekeeping gene β-actin are designed by Primer
Premier 5.0 (Table 1). Real time-polymerase chain reaction
(RT-PCR) was performed by using an ABI 7300 Sequence
Detection System (Applied Biosystems, Foster City, CA)
using SYBR green. After initial denaturation for 30 sec
at 95°C, a two-step cycling procedure (95°C for 5 sec,
60°C for 31 sec) was used for 40 cycles. The relative
gene expressions was normalized to the level of β-actin
transcripts and quantified by the △△CT method using
a 7300 System Sequence Detection software (Applied
Biosystems, Foster City, CA). All reactions were performed
at least in duplicate for each sample.
Cytokine assay
Plasma cytokine content was determined using enzyme-
linked immunosorbent assays. IL-22 was measured byTable 1 Sequences of primers for real-time RT-PCR
Molecule Sequence (5’ ~ 3’)
COL1-A1 sense: CGCCATCAAGGTCTACTGC
GenBank: 12842 anti-sense: GAATCCATCGGTCATGCTCT
COL3-A1 sense: GTGGCTCTAATGGCATCAAAG
GenBank: 12825 anti-sense: ATGTGGTCCAACTGGTCCTCTG
MMP9 sense: TGGGACCATCATAACATCAC
GenBank: 17395 anti-sense: GATACCCGTCTCCGTGCT
TIMP-1 sense: CTTGGTTCCCTGGCGTACTC
GenBank: 21857 anti-sense: ACCTGATCCGTCCACAAACAG
β-actin sense: AATTCCATCATGAAGTGTGA
GenBank: 11461 anti-sense: ACTCCTGCTTGCTGATCCACthe Mouse IL-22 Platinum Enzyme linked immunosorb-
ent assay (ELISA) (eBioscience, BMS6022, USA). The
levels of COL1-A1, TIMP-1 and MMP9 in mice were also
determined by ELISA (Cusabio Biotech, China and Boster,
China). The sensitivity of ELISA kits for IL-22, COL1-A1,
TIMP-1 and MMP9 was 5, 78, 39 and 5 pg/ml, respect-
ively, and no cross-reactivity was detected. All samples
were measured in triplicate.
Statistical analysis
Data were expressed as the means ± standard deviation
(SD). Statistical analyses were performed with one-way
ANOVA. Correlations were determined by Spearman rank
correlation coefficients. Kaplan-Meier survival curve was
used to estimate the survival rate of mice and the log-rank
test was used to assess the difference of the survival rate
among mouse groups. All statistical analyses of data
were performed using SPSS 17.0 (IBM, USA). Differ-
ences at p < 0.05 among the means were deemed to be
statistically significant.
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